Single arm, single site, open-label Phase II study of the effects of oral olaparib in
participants with metastatic renal cell carcinoma that harbor an inactivating mutation in
BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A,
RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint
inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1
- Willing and able to provide written informed consent. Provision of informed consent is
required prior to any study procedures.
- Patients aged 18 years of age or older.
- Histological proof of renal cell carcinoma (both clear cell and non-clear cell
- Metastatic (AJCC Stage IV) renal cell carcinoma.
- Somatic or germline mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C,
BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L as documented by a
clinical CLIA-grade, tissue, saliva or blood-based genetic test.
- At least one prior treatment with an anti-angiogenic agent or immune checkpoint
- Any number of prior systemic therapies is allowed (cytokine, anti-angiogenic, mTOR,
immune checkpoint blockage or clinical trial).
- Must have measurable disease as defined by RECIST 1.1 criteria.
- Participants must have normal organ and bone marrow function measured within 28 days
prior to administration of study treatment as defined below:
- Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT))
/ Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤
2.5 x institutional ULN unless liver metastases are present in which case they
must be ≤ 5 x ULN.
Note: Patients with elevations in bilirubin, AST, or ALT should be thoroughly evaluated for
the etiology of this abnormality prior to entry and patients with evidence of viral
infection should be excluded.
- Patients must have a creatinine clearance ≥ 51 mL/min calculated by Cockroft-Gault
formula or 24 hour urine test.
- ECOG PS ≤ 1.
- Participants must have a life expectancy ≥ 16 weeks.
- Postmenopausal or evidence of non-childbearing status for women of childbearing
potential: negative urine or serum pregnancy test within 28 days of study
treatment and confirmed prior to treatment on day 1.
Postmenopausal is defined as:
- Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments.
- Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post
menopausal range for women under 50 years old.
- Radiation-induced oophorectomy with last menses > 1 year ago.
- Chemotherapy-induced menopause with > 1 year interval since last menses.
- Surgical sterilization (bilateral oophorectomy or hysterectomy).
- Male patients must use a condom during treatment and for 3 months after the last dose
of olaparib when having sexual intercourse with a pregnant woman or with a woman of
childbearing potential. Female partners of male patients should also use a highly
effective form of contraception if they are of childbearing potential.
- Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years
except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer
of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial
carcinoma. Patients with a history of localized triple negative breast cancer may be
eligible, provided they completed their adjuvant chemotherapy > 3 years prior to
registration, and that the patient remains free of recurrent or metastatic disease.
- Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence
of brain metastases is not required. The patient can receive a stable dose of
corticosteroids before and during the study as long as these were started at least 4
weeks prior to treatment. Patients with spinal cord compression unless considered to
have received definitive treatment for this and evidence of clinically stable disease
for 28 days.
- Previous allogenic bone marrow transplant or double umbilical cord blood
- Judgment by the investigator that the patient should not participate in the study if
the patient is unlikely to comply with study procedures, restrictions and
- Breast feeding women.
- Use of any prohibited concomitant medications within the prior 2 weeks.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
staff and/or staff at the study site).
- Participation in another clinical study with an investigational product during the
last 2 weeks.
- Patients receiving any systemic chemotherapy or radiotherapy (except for palliative
reasons) within 3 weeks prior to study treatment.
- Any previous treatment with PARP inhibitor, including olaparib.
- Resting ECG with QTc > 500 ms and/or indication of uncontrolled cardiac conditions, as
judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic
arrhythmia, congestive heart failure, electrolyte disturbances, etc.), or patients
with congenital and/or family history of long QT syndrome.
- Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin,
clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,
saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g.
ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout
period prior to starting olaparib is 2 weeks. During the study, if co-administration
of a strong or moderate inhibitor is required because there is no suitable alternative
medication, exception to this criterion may be allowed with a suitable dose reduction
- Concomitant use of known strong CYP3A inducers (e.g. phenobarbital, phenytoin,
rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or
moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout
period prior to starting olaparib is 5 weeks for phenobarbital or enzalutamide and 3
weeks for other agents.
- Persistent toxicities (> Common Terminology Criteria for Adverse Event (CTCAE) grade
2) caused by previous cancer therapy, excluding alopecia.
- Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with
features suggestive of MDS/AML.
- Major surgery within 2 weeks of starting study treatment and patients must have
recovered from any effects of any major surgery.
- Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant
systemic disease or active, uncontrolled infection. Examples include, but are not
limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial
infarction, uncontrolled major seizure disorder, extensive interstitial bilateral lung
disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder
that prohibits obtaining informed consent.
- Unable to swallow orally administered medication and patients with gastrointestinal
disorders likely to interfere with absorption of the study medication.
- Immunocompromised patients, e.g., patients who are known to be serologically positive
for human immunodeficiency virus (HIV).
- Known hypersensitivity to olaparib or any of the excipients of the product.
- Known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the
infection through blood or other body fluids.
- Packed red blood cells and/or platelet transfusions within the last 28 days prior to